Publications - MIS-lab

On this page you will find a list of selected publications from the MIS-lab.

Selected Publications

Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data.
van der Lee M, Allard WG, Vossen RHAM, Baak-Pablo RF, Menafra R, Deiman BALM, Deenen MJ, Neven P, Johansson I, Gastaldello S, Ingelman-Sundberg M, Guchelaar HJ, Swen JJ, Anvar SY.
Sci Transl Med. 2021 Jul 21;13(603):eabf3637.

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.
Jukić MM, Smith RL, Molden E, Ingelman-Sundberg M.
Clin Pharmacol Ther. 2021 Mar 31. doi: 10.1002/cpt.2246.

A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS, Haslemo T, Jukic MM, Ivanov M, Ingelman-Sundberg M, Molden E, Kringen MK.
Clin Pharmacol Ther. 2021 Mar 24. doi: 10.1002/cpt.2233.

Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low clearance.
Riede J, Wollmann BM, Molden E, Ingelman-Sundberg M.
Drug Metab Dispos. 2021 Jun 1:DMD-AR-2020-000340.

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM.
JAMA Psychiatry. 2021 Mar 1;78(3):270-280.

Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.
Smutny T, Hyrsova L, Braeuning A, Ingelman-Sundberg M, Pavek P.
Arch Toxicol. 2021 Jan;95(1):11-25

Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M
Lancet Psychiatry 2019 May;6(5):418-426

A 3D Cell Culture Model Identifies Wnt/β-Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration.
Oliva-Vilarnau N, Vorrink SU, Ingelman-Sundberg M, Lauschke VM
Adv Sci (Weinh) 2020 Aug;7(15):2000248

Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Hendriks DFG, Vorrink SU, Smutny T, Sim SC, Nordling Å, Ullah S, et al
Clin. Pharmacol. Ther. 2020 Apr;():

Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis.
Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks DFG, Nordling Å, Johansson I, et al
Cells 2020 Apr;9(4):

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.
Lauschke VM, Zhou Y, Ingelman-Sundberg M
Pharmacol. Ther. 2019 05;197():122-152

AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis.
Cordero-Herrera I, Kozyra M, Zhuge Z, McCann Haworth S, Moretti C, Peleli M, et al
Proc. Natl. Acad. Sci. U.S.A. 2019 01;116(1):217-226

Human hepatic 3D spheroids as a model for steatosis and insulin resistance.
Kozyra M, Johansson I, Nordling Å, Ullah S, Lauschke VM, Ingelman-Sundberg M
Sci Rep 2018 Sep;8(1):14297

Integrating rare genetic variants into pharmacogenetic drug response predictions.
Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM
Hum. Genomics 2018 05;12(1):26

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M
Am J Psychiatry 2018 05;175(5):463-470

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.
Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, et al
Genet. Med. 2018 06;20(6):622-629

Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities.
Lauschke VM, Barragan I, Ingelman-Sundberg M
Annu. Rev. Pharmacol. Toxicol. 2018 01;58():161-185

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.
Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, et al
Mol. Psychiatry 2017 Aug;22(8):1224

Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.
Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, et al
Drug Metab. Dispos. 2017 04;45(4):419-429

Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation.
Lauschke VM, Vorrink SU, Moro SM, Rezayee F, Nordling Å, Hendriks DF, et al
Hepatology 2016 11;64(5):1743-1756

Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability.
Hendriks DF, Fredriksson Puigvert L, Messner S, Mortiz W, Ingelman-Sundberg M
Sci Rep 2016 10;6():35434

Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression.
Ivanov M, Kals M, Lauschke V, Barragan I, Ewels P, Käller M, et al
Nucleic Acids Res. 2016 08;44(14):6756-69

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.
Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, et al
Sci Rep 2016 05;6():25187

Full list of publications

Full list of publications from Magnus Ingelman-Sundberg.